预约演示

Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)

2023-03-20

上市批准

MINNETONKA, Minn.--(BUSINESS WIRE)-- Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division (APD), has just started to commercialize its abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its Generic Version of Magnesium Sulfate in Water for Injection, 2 g/50 mL (40 mg/mL), 4 g/100 mL (40 mg/mL) and 4 g/50 mL (80 mg/mL), in Non-PVC, Single-Patient Use Containers (Magnesium Sulfate Injection). This press release features multimedia. View the full release here: Alter Pharma #MakingAffordableMedicinesAvailableToAll Every day we ensure equal access to medicines and continuity of treatment for patients. We make sure patients get the highest level of quality and safety at an affordable price and their treatment continues without interruption. (Graphic: Business Wire) Magnesium Sulfate Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia. When used judiciously, it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. Magnesium Sulfate Injection is currently on the ASHP drug shortage list of essential medications. This latest launch of Magnesium Sulfate Injection will help reduce the recent supply issues for the product experienced in the U.S. This achievement marks the second ANDA commercialization for Milla Pharmaceuticals Inc. and the third for an Alter Pharma Group product in the U.S. market. “It’s very exciting to see another of our products hit the U.S. market, and less than 2 years after our launch of Sodium Acetate Injection, and less than three years after the launch of our generic injectable Acetaminophen (Paracetamol IV),” said Erik Lazarich, President of the U.S. Operations of the Alter Pharma Group and Director of Milla Pharmaceuticals Inc. “Moreover, this is another product considered to be in shortage. By launching our Magnesium Sulfate Injection and providing this high-quality generic equivalent to patients in need, we directly contribute to the realization of our ambition to make affordable medicines available to all, whether that is in the EU or the U.S.” “We are very pleased to launch this important product with our partner Milla Pharmaceuticals. This product is consistently on the FDA’s Shortage List and this launch will enable the product to be utilized by patients that desperately need the drug. We look forward to additional new launches with Milla Pharmaceuticals in the future,” said Jeffrey Yordon, President of APD. About Milla Pharmaceuticals Inc. Milla Pharmaceuticals Inc., a wholly-owned subsidiary of the Alter Pharma Group, is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market focused on niche injectable and solution products for hospitals and clinics. More info: About - Milla Pharmaceuticals Inc. About Athenex Pharmaceutical Division Athenex Pharmaceuticals is an innovative global pharmaceutical company committed to researching, developing, manufacturing, and delivering the highest quality sterile injectable products. Our quest for innovation brings unique presentations to the US market, and our commitment to excellence drives us to meet the highest possible standards. More info: About Athenex Pharma View source version on businesswire.com: Contacts Erik Lazarich President Milla Pharmaceuticals Inc. Mobile: +1 651-231-1042 │ Office: +1 952-449-5154 │ email: erik.lazarich@millapharma.com 601 Carlson Parkway │ Suite 1050 │ Minnetonka, Minnesota 55305 millapharmaceuticals.com Source: Milla Pharmaceuticals Inc. Smart Multimedia Gallery Logo Logo Photo Alter Pharma #MakingAffordableMedicinesAvailableToAll Every day we ensure equal access to medicines and continuity of treatment for patients. We make sure patients get the highest level of quality and safety at an affordable price and their treatment continues without interruption. (Graphic: Business Wire) View this news release and multimedia online at: